Compare TVRD & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TVRD | GSIW |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7M | 14.6M |
| IPO Year | 2013 | 2022 |
| Metric | TVRD | GSIW |
|---|---|---|
| Price | $1.09 | $10.41 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $8.88 | N/A |
| AVG Volume (30 Days) | ★ 207.0K | 3.2K |
| Earning Date | 11-13-2026 | 08-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $911,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 959.30 | N/A |
| 52 Week Low | $0.77 | $0.05 |
| 52 Week High | $5.69 | $38.55 |
| Indicator | TVRD | GSIW |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 45.40 |
| Support Level | $0.85 | $9.39 |
| Resistance Level | $2.02 | $12.32 |
| Average True Range (ATR) | 0.17 | 0.52 |
| MACD | 0.05 | 0.23 |
| Stochastic Oscillator | 41.46 | 45.24 |
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Garden Stage Ltd, through its subsidiaries is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; asset management services; investment advisory services; due diligence services; and introduction and referral services. The company operates in a single segment and derives all of its revenue from Hong Kong.